{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:28:34Z","timestamp":1773966514986,"version":"3.50.1"},"reference-count":105,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,3,23]],"date-time":"2006-03-23T00:00:00Z","timestamp":1143072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The incidence of non\u2010Hodgkin's lymphoma (NHL) has markedly increased in the US and other westernized countries in recent years and presents a considerable clinical challenge. NHL is divided into subtypes that follow an aggressive or indolent course. Follicular lymphoma (FL), the most common indolent subtype, and mantle cell lymphoma (MCL), an aggressive subtype that accounts for approximately 5% of cases, are generally incurable. MCL has a relatively poor prognosis, with a median survival of 3\u20134 years. Despite improving response rates with new agents and regimens, the lack of demonstrated improvement in overall survival in many subtypes supports the development of novel approaches, such as proteasome inhibition. Bortezomib is the first proteasome inhibitor to be evaluated in human studies. It has already been approved as second\u2010line treatment in multiple myeloma and is now under active investigation in NHL. The US FDA has granted bortezomib fast\u2010track designation for relapsed and refractory MCL. <jats:italic>In vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> studies have demonstrated single\u2010agent activity against various lymphoid tumors, and additive or synergistic effects in combination with other agents, including standard chemotherapy drugs employed in NHL. Phase 2 clinical trials indicate that bortezomib is well tolerated and active in several NHL subtypes, with response rates of 18\u201360% in FL and 39\u201356% in MCL. A number of combination trials are currently underway with a range of standard agents. Bortezomib has the potential to play a significant role throughout the NHL treatment algorithm in the future. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.21805","type":"journal-article","created":{"date-parts":[[2006,3,24]],"date-time":"2006-03-24T01:46:48Z","timestamp":1143164808000},"page":"971-979","source":"Crossref","is-referenced-by-count":41,"title":["Proteasome inhibition with bortezomib: A new therapeutic strategy for non\u2010Hodgkin's lymphoma"],"prefix":"10.1002","volume":"119","author":[{"given":"John P.","family":"Leonard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,6,5]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207843"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.n.025"},{"key":"e_1_2_7_4_2","volume-title":"GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide","author":"Ferlay J","year":"2004"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2004.02.007"},{"key":"e_1_2_7_7_2","first-page":"39","article-title":"Treatment of follicular non\u2010Hodgkin's lymphoma","volume":"4","author":"Maloney DG","year":"2005","journal-title":"Curr Hematol Rep"},{"issue":"1","key":"e_1_2_7_8_2","first-page":"S72","article-title":"Novel treatment strategies in follicular lymphoma","volume":"83","author":"Buske C","year":"2004","journal-title":"Ann Hematol"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001616917"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.170"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.172"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20483"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.004"},{"key":"e_1_2_7_17_2","first-page":"v51","article-title":"Rituximab plus mitoxantrone, chlorambucil, prednisolon (R\u2010MCP) is superior to MCP alone in advanced indolent and follicular lymphoma\u2014results of a phase III study (OSH039)","volume":"16","author":"Herold M","year":"2005","journal-title":"Ann Oncol"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0774-2"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-003-0023-x"},{"key":"e_1_2_7_20_2","first-page":"879","article-title":"Mantle cell lymphoma: clinicopathologic features and treatments","volume":"17","author":"Kauh J","year":"2003","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001616926"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"e_1_2_7_25_2","doi-asserted-by":"crossref","first-page":"6a","DOI":"10.1182\/blood.V104.11.8.8","article-title":"Nordic mantle cell lymphoma (MCL) project: prolonged follow\u2010up of 86 patients treated with BEAM\/BEAC + PBSCT confirms that addition of high\u2010dose Ara\u2010C and rituximab to CHOP induction + in\u2010vivo purging with rituximab increases clinical and molecular response rates, PCR\u2010neg. grafts, failure\u2010free, relapse\u2010free and overall survival","volume":"104","author":"Geisler CH","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.980"},{"key":"e_1_2_7_27_2","first-page":"7","article-title":"Treatment of diffuse large B\u2010cell lymphoma","volume":"4","author":"Coiffier B","year":"2005","journal-title":"Curr Hematol Rep"},{"key":"e_1_2_7_28_2","article-title":"Diffuse aggressive lymphoma","volume":"221","author":"Fisher RI","year":"2004","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.021"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120030218"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2002.n.011"},{"key":"e_1_2_7_32_2","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams J","year":"1999","journal-title":"Cancer Res"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1361"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.07.006"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/med.1009"},{"key":"e_1_2_7_36_2","first-page":"6316","article-title":"The proteasome as a target for cancer therapy","volume":"9","author":"Voorhees PM","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.003"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.32.22123"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-5521(01)00056-4"},{"key":"e_1_2_7_40_2","first-page":"191","article-title":"Targeting proteasome inhibition in hematologic malignancies","volume":"7","author":"Hideshima T","year":"2003","journal-title":"Rev Clin Exp Hematol"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006321828515"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(03)02647-3"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/107327480301000502"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5234.286"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5234.283"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.4.2200"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.3.990.415a08_990_995"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50049"},{"key":"e_1_2_7_49_2","first-page":"2360","article-title":"Constitutive activation of NF\u2010kappaB in primary adult T\u2010cell leukemia cells","volume":"93","author":"Mori N","year":"1999","journal-title":"Blood"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.1200"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199805143382003"},{"key":"e_1_2_7_52_2","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1182\/blood.V96.7.2537.h8002537_2537_2542","article-title":"Inhibition of NF\u2010kappa B induces apoptosis of KSHV\u2010infected primary effusion lymphoma cells","volume":"96","author":"Keller SA","year":"2000","journal-title":"Blood"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110480200"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(98)00029-8"},{"key":"e_1_2_7_55_2","first-page":"3071","article-title":"The proteasome inhibitor PS\u2010341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima T","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2543"},{"key":"e_1_2_7_57_2","first-page":"4996","article-title":"Proteasome inhibitor PS\u2010341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model","volume":"62","author":"LeBlanc R","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2004.tb03200.x"},{"key":"e_1_2_7_59_2","first-page":"1145","article-title":"Mechanisms of proteasome inhibitor PS\u2010341\u2010induced G(2)\u2010M\u2010phase arrest and apoptosis in human non\u2010small cell lung cancer cell lines","volume":"9","author":"Ling YH","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0811-4"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2004.s.021"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.88"},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403460"},{"key":"e_1_2_7_64_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.4.1.1379"},{"key":"e_1_2_7_65_2","doi-asserted-by":"crossref","first-page":"900a","DOI":"10.1182\/blood.V104.11.3294.3294","article-title":"Mantle cell and follicular lymphoma samples demonstrate differeing sensitivity to bortezomib in a primary culture system","volume":"104","author":"Maharaj L","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.2.619"},{"key":"e_1_2_7_67_2","doi-asserted-by":"crossref","first-page":"629a","DOI":"10.1182\/blood.V104.11.2287.2287","article-title":"Cell cycle dysregulation represents an early effect of proteasome inhibitor bortezomib in mantle cell lymphoma","volume":"104","author":"Hutter G","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_68_2","first-page":"465a","article-title":"Antitumor activity of the proteasome inhibitor PS\u2010341 in mantle cell lymphoma B cells","volume":"98","author":"Pham L","year":"2001","journal-title":"Blood"},{"key":"e_1_2_7_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403400"},{"key":"e_1_2_7_70_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1768"},{"key":"e_1_2_7_71_2","first-page":"1136","article-title":"The proteasome inhibitor PS\u2010341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents","volume":"9","author":"Ma MH","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_72_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.59.3.1"},{"key":"e_1_2_7_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2004.04.029"},{"key":"e_1_2_7_74_2","first-page":"304a","article-title":"Mechanisms of enhanced cytotoxicity from docetaxel\/PS\u2010341 combination in non\u2010small cell lung carcinoma (NSCLC)","volume":"21","author":"Gumerlock P","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_7_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2004.07.010"},{"key":"e_1_2_7_76_2","first-page":"389a","article-title":"Sensitivity, schedule\u2010dependence and molecular effects of the proteasome inhibitor bortezomib in non\u2010Hodgkin's lymphoma cells","volume":"104","author":"Goy A","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_77_2","article-title":"Active combination therapy of bortezomib and rituximab in an in vitro and in vivo DLBCL model","volume":"45","author":"De Vos S","year":"2004","journal-title":"Proc AACR"},{"key":"e_1_2_7_78_2","doi-asserted-by":"crossref","first-page":"765a","DOI":"10.1182\/blood.V104.11.2798.2798","article-title":"Treatment of B\u2010CLL cells with bortezomib and rituximab reduces cell viability in vitro","volume":"104","author":"Lewintre EJ","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_79_2","doi-asserted-by":"crossref","first-page":"288b","DOI":"10.1182\/blood.V104.11.4822.4822","article-title":"Cytotoxic effect of proteasome inhibitor bortezomib in combination with ourine nucleoside analogues on chronic lymphocytic leukemis cells in vitro","volume":"104","author":"Smolewski P","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_80_2","first-page":"237b","article-title":"Bortezomib sensitizes non\u2010Hodgkin's lymphoma cells to apoptosis induced by antibodies to TRAIL receptors TRAIL\u2010R1 and TRAIL\u2010R2","volume":"104","author":"Smith M","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_81_2","first-page":"681a","article-title":"Combined targeting of the proteasome and Bcl\u20102 sensitizes human B\u2010cell lymphoma and multiple myeloma to cyclophosphamide in in vitro and in vivo models of these diseases","volume":"104","author":"O'Connor O","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01446-8"},{"key":"e_1_2_7_83_2","first-page":"175a","article-title":"A multicenter experience with single agent bortezomib in non\u2010Hodgkin's lymphoma reveals marked differences in sub\u2010type sensitivity to proteasome inhibition","volume":"104","author":"O'Connor O","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_84_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_7_85_2","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1200\/jco.2005.23.16_suppl.6563","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study","volume":"23","author":"Goy A","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_86_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.1386.1386","article-title":"Phase II clinical study of bortezomib (velcade) in patients with relapsed\/ refractory non\u2010Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)","volume":"104","author":"Strauss SJ","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_87_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.608.608"},{"key":"e_1_2_7_88_2","first-page":"896a","article-title":"Antitumor activity of bortezomib (PS\u2010341; velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM)","volume":"104","author":"Chen C","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_89_2","doi-asserted-by":"crossref","first-page":"293b","DOI":"10.1182\/blood.V104.11.4841.4841","article-title":"Phase 2 study of three doses of single agent bortezomib in patients with fludarabine\u2010refractory B\u2010cell CLL","volume":"104","author":"Faderl S","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_90_2","first-page":"v136","article-title":"Phase 2 study of bortezomib and rituximab in patients with indolent non\u2010Hodgkin's lymphoma (NHL)","volume":"16","author":"Saleh M","year":"2005","journal-title":"Ann Oncol"},{"key":"e_1_2_7_91_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2911"},{"key":"e_1_2_7_92_2","doi-asserted-by":"crossref","first-page":"389a","DOI":"10.1182\/blood.V104.11.1385.1385","article-title":"Phase I\/II study of bortezomib alone and bortezomib with dose\u2010adjusted EPOCH chemotherapy in relapsed or refractory aggressive B\u2010cell lymphoma","volume":"104","author":"Dunleavy K","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05519.x"},{"key":"e_1_2_7_94_2","doi-asserted-by":"crossref","first-page":"598s","DOI":"10.1200\/jco.2005.23.16_suppl.6653","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study","volume":"23","author":"Harousseau J","year":"2005","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_95_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.389"},{"key":"e_1_2_7_96_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674"},{"key":"e_1_2_7_97_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"e_1_2_7_98_2","first-page":"2505","article-title":"A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies","volume":"8","author":"Aghajanian C","year":"2002","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_99_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"e_1_2_7_100_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05188.x"},{"key":"e_1_2_7_101_2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/jco.2004.22.90140.6511","article-title":"Bortezomib vs dexamethasone in relapsed multiple myeloma: a phase 3 randomized study","volume":"22","author":"Richardson P","year":"2004","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_102_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_7_103_2","first-page":"902a","article-title":"A phase II study of bortezomib in patients with mantle cell lymphoma","volume":"102","author":"Assouline S","year":"2003","journal-title":"Blood"},{"key":"e_1_2_7_104_2","first-page":"64a","article-title":"Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a phase I\/II study","volume":"104","author":"Berenson J","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_105_2","article-title":"Phase II study of velcade and doxil in combination with low\u2010dose thalidomide (VDT) as salvage therapy for patients with relapsed or refractory multiple myeloma or Waldenstrom's macroglobulinemia","volume":"665","author":"Chanan\u2010Khan AA","year":"2004","journal-title":"Blood"},{"key":"e_1_2_7_106_2","first-page":"677a","article-title":"Arsenic trioxide shows synergistic anti\u2010myeloma effects when combined with bortezomib and melphalan in vitro and helps overcome resistance of multiple myeloma cells to these treatments in vivo","volume":"104","author":"Campbell RA","year":"2004","journal-title":"Blood"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.21805","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.21805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T01:26:08Z","timestamp":1695950768000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.21805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,5]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1002\/ijc.21805"],"URL":"https:\/\/doi.org\/10.1002\/ijc.21805","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,5]]}}}